LY2584702 is a selective inhibitor of p38α mitogen-activated protein kinase (MAPK), a key enzyme involved in inflammatory signaling pathways. It has been investigated primarily for its potential in treating inflammatory and autoimmune conditions, such as rheumatoid arthritis and psoriasis. By blocking p38α activity, LY2584702 helps reduce the production of pro-inflammatory cytokines like TNF-α and IL-1β, which play central roles in chronic inflammation. The compound has undergone early-phase clinical trials to evaluate its safety, pharmacokinetics, and efficacy in modulating inflammatory responses. Its development highlights the therapeutic strategy of targeting intracellular signaling kinases to manage immune-mediated diseases.